{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:21:14Z","timestamp":1783502474045,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"DOI":"10.7759\/cureus.112255","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:12:35Z","timestamp":1783501955000},"source":"Crossref","is-referenced-by-count":0,"title":["Direct Immunofluorescence Intensity as a Supportive Marker of Clinical Severity in Pemphigus Vulgaris"],"prefix":"10.7759","author":[{"given":"Harshita Reddy","family":"Bondugula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samhitha","family":"Mallavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejaswi","family":"Kothapally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Babu","family":"Venna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriteja","family":"Vemulapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmohan","family":"G","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidhar","family":"Chinnapaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt E","year":"2019","unstructured":"Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019, 394:882-94. 10.1016\/S0140-6736(19)31778-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90360-b","article-title":"Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion","volume":"67","author":"Amagai M","year":"1991","unstructured":"Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991, 67:869-77. 10.1016\/0092-8674(91)90360-b","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra061111","article-title":"Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome","volume":"355","author":"Stanley JR","year":"2006","unstructured":"Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med. 2006, 355:1800-10. 10.1056\/NEJMra061111","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: Recommendations of an international panel of experts","volume":"82","author":"Murrell DF","year":"2020","unstructured":"Murrell DF, Pe\u00f1a S, Joly P, et al.. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol. 2020, 82:575-585.e1. 10.1016\/j.jaad.2018.02.021","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.117518","article-title":"Immunofluorescence in dermatology","volume":"45","author":"Mutasim DF","year":"2001","unstructured":"Mutasim DF, Adams BB. Immunofluorescence in dermatology. J Am Acad Dermatol. 2001, 45:803-22; quiz 822-4. 10.1067\/mjd.2001.117518","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus","volume":"129","author":"Rosenbach M","year":"2009","unstructured":"Rosenbach M, Murrell DF, Bystryn JC, et al.. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009, 129:2404-10. 10.1038\/jid.2009.72","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.8175","article-title":"Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score","volume":"150","author":"Rahbar Z","year":"2014","unstructured":"Rahbar Z, Daneshpazhooh M, Mirshams-Shahshahani M, et al.. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score. JAMA Dermatol. 2014, 150:266-72. 10.1001\/jamadermatol.2013.8175","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large International Validation of ABSIS and PDAI Pemphigus Severity Scores","volume":"139","author":"H\u00e9bert V","year":"2019","unstructured":"H\u00e9bert V, Boulard C, Houivet E, et al.. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. J Invest Dermatol. 2019, 139:31-7. 10.1016\/j.jid.2018.04.042","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.102355","article-title":"Immunofluorescence in dermatology","volume":"78","author":"Chhabra S","year":"2012","unstructured":"Chhabra S, Minz RW, Saikia B. Immunofluorescence in dermatology. Indian J Dermatol Venereol Leprol. 2012, 78:677-91. 10.4103\/0378-6323.102355","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman KE","year":"2001","unstructured":"Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001, 144:775-80. 10.1046\/j.1365-2133.2001.04132.x","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(99)70183-0","article-title":"The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile","volume":"40","author":"Amagai M","year":"1999","unstructured":"Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999, 40:167-70. 10.1016\/s0190-9622(99)70183-0","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.159.4.2010","article-title":"Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins","volume":"159","author":"Ishii K","year":"1997","unstructured":"Ishii K, Amagai M, Hall RP, et al.. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997, 159:2010-7.","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.2.143","article-title":"Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool","volume":"135","author":"Lenz P","year":"1999","unstructured":"Lenz P, Amagai M, Volc-Platzer B, Stingl G, Kirnbauer R. Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool. Arch Dermatol. 1999, 135:143-8. 10.1001\/archderm.135.2.143","journal-title":"Arch Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.25780","article-title":"Study of desmoglein 1 and 3 antibody levels in relation to disease severity in Indian patients with pemphigus","volume":"72","author":"Kumar B","year":"2006","unstructured":"Kumar B, Arora S, Kumaran MS, Jain R, Dogra S. Study of desmoglein 1 and 3 antibody levels in relation to disease severity in Indian patients with pemphigus. Indian J Dermatol Venereol Leprol. 2006, 72:203-6. 10.4103\/0378-6323.25780","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2016.10.003","article-title":"Validation studies of outcome measures in pemphigus","volume":"2","author":"Hanna S","year":"2016","unstructured":"Hanna S, Kim M, Murrell DF. Validation studies of outcome measures in pemphigus. Int J Womens Dermatol. 2016, 2:128-39. 10.1016\/j.ijwd.2016.10.003","journal-title":"Int J Womens Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly P","year":"2020","unstructured":"Joly P, Horvath B, Patsatsi \u0391, et al.. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020, 34:1900-13. 10.1111\/jdv.16752","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth VP","year":"2021","unstructured":"Werth VP, Joly P, Mimouni D, et al.. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021, 384:2295-305. 10.1056\/NEJMoa2028564","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01190","article-title":"Non-desmoglein antibodies in patients with pemphigus vulgaris","volume":"9","author":"Amber KT","year":"2018","unstructured":"Amber KT, Valdebran M, Grando SA. Non-desmoglein antibodies in patients with pemphigus vulgaris. Front Immunol. 2018, 9:1190. 10.3389\/fimmu.2018.01190","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02571","article-title":"Assessing the correlation between disease severity indices and quality of life measurement tools in pemphigus","volume":"10","author":"Krain RL","year":"2019","unstructured":"Krain RL, Kushner CJ, Tarazi M, et al.. Assessing the correlation between disease severity indices and quality of life measurement tools in pemphigus. Front Immunol. 2019, 10:2571. 10.3389\/fimmu.2019.02571","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4317\/jced.56289","article-title":"Evaluation of desmoglein 1 and 3 autoantibodies in pemphigus vulgaris: correlation with disease severity","volume":"12","author":"Delavarian Z","year":"2020","unstructured":"Delavarian Z, Layegh P, Pakfetrat A, Zarghi N, Khorashadizadeh M, Ghazi A. Evaluation of desmoglein 1 and 3 autoantibodies in pemphigus vulgaris: correlation with disease severity. J Clin Exp Dent. 2020, 12:e440-5. 10.4317\/jced.56289","journal-title":"J Clin Exp Dent"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/509735-direct-immunofluorescence-intensity-as-a-supportive-marker-of-clinical-severity-in-pemphigus-vulgaris","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:12:36Z","timestamp":1783501956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/509735-direct-immunofluorescence-intensity-as-a-supportive-marker-of-clinical-severity-in-pemphigus-vulgaris"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.112255","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}